


## Trihydroxycholestanic acid

Cat. No.:	HY-113335
CAS No.:	547-98-8
Molecular Formula:	C <sub>27</sub> H <sub>46</sub> O <sub>5</sub>
Molecular Weight:	450.65
Target:	Endogenous Metabolite
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Trihydroxycholestanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Refsum Disease, D Bifunctional Protein Deficiency and Infantile Refsum Disease <sup>[1][2][3][4]</sup> .
<b>In Vitro</b>	Endogenous metabolites is defined as those that are annotated by Kyoto Encyclopedia of Genes and Genomes as substrates or products of the ~1900 metabolic enzymes encoded in our genome. It is clear in the body of literature that there are documented toxic properties for many of these metabolites <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Baumgartner MR, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. *Ann Neurol*. 1998 Nov;44(5):720-30.
- [2]. Poll-The BT, et al. Infantile Refsum's disease: biochemical findings suggesting multiple peroxisomal dysfunction. *J Inherit Metab Dis*. 1986;9(2):169-74.
- [3]. Rizzo C, et al. Characteristic acylcarnitine profiles in inherited defects of peroxisome biogenesis: a novel tool for screening diagnosis using tandem mass spectrometry. *Pediatr Res*. 2003 Jun;53(6):1013-8.
- [4]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. *Oncogene*. 2020 Aug;39(35):5709-5720.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA